Key Developments: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,361.00GBp
28 Jul 2014
Price Change (% chg)

-31.00p (-0.71%)
Prev Close
4,392.00p
Open
4,400.00p
Day's High
4,403.00p
Day's Low
4,358.00p
Volume
1,735,987
Avg. Vol
3,549,141
52-wk High
4,946.41p
52-wk Low
3,085.21p

Search Stocks

Latest Key Developments (Source: Significant Developments)

AstraZeneca completes purchase of Sumitomo Chemical’s stake in AstraZeneca K.K.
Tuesday, 25 Mar 2014 08:00pm EDT 

AstraZeneca plc:Completes purchase of Sumitomo Chemical's remaining shares in AstraZeneca K.K.Says through the acquisition aims to reinforces focus on Japan as a key growth platform.Purchase value about 10 billion yen ($102 million).  Full Article

AstraZeneca says Forxiga receives regulatory approval in Japan for treatment of type 2 diabetes
Sunday, 23 Mar 2014 08:00pm EDT 

AstraZeneca PLC:Says the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, as a once-daily oral treatment for type 2 diabetes.Says the company and Ono Pharmaceutical entered into an agreement to co-promote FORXIGA on Dec. 3.The FORXIGA application was submitted to the MHLW by Bristol-Myers Squibb K.K.  Full Article

AstraZeneca PLC launches NEXIUM (Esomeprazole Magnesium) Direct-to-Patient Program
Wednesday, 19 Mar 2014 08:00am EDT 

AstraZeneca PLC:Launches NEXIUM Direct, a program that provides eligible patients option of having brand-name NEXIUM delivered directly to their home.NEXIUM Direct is part of AstraZeneca Direct, a web-based offering that delivers select brand name prescription medications from AstraZeneca directly to person's home.Medications are dispensed by team of registered pharmacists and certified pharmacy technicians available through collaboration with Eagle Pharmacy, a trusted pharmacy partner.  Full Article

AstraZeneca PLC announces sale of Alderley Park Site
Wednesday, 12 Mar 2014 03:00am EDT 

AstraZeneca PLC:Says the sale of its Alderley Park site in Cheshire, UK, to Manchester Science Parks (MSP).AstraZeneca expects to complete the sale by end of March 2014 and will remain a key tenant on the site.  Full Article

AstraZeneca PLC .S. FDA approves Bydureon Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes
Monday, 3 Mar 2014 02:00am EST 

AstraZeneca PLC:U.S. Food and Drug Administration (FDA) has approved the Bydureon Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.Bydureon should not be used for treatment of patients with type 1 diabetes or diabetic ketoacidosis.Bydureon is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise.Bydureon is not a substitute for insulin.Says concurrent use of Bydureon with insulin has not been studied and is not recommended.Bydureon is the first and only once-weekly medicine for adults with type 2 diabetes.  Full Article

U.S. FDA approves AstraZeneca PLC's orphan drug Myalept
Tuesday, 25 Feb 2014 02:08pm EST 

AstraZeneca PLC:Announced that the U.S. Food and Drug Administration (FDA) has approved Myalept.Myalept is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.MYALEPT, a recombinant analog [laboratory-created form] of human leptin, is the first and only treatment approved by the FDA for these patients.  Full Article

AstraZeneca PLC declares second interim dividend
Thursday, 6 Feb 2014 02:04am EST 

AstraZeneca PLC:Declares a second interim dividend of $1.90 per share, bringing the dividend for the full year to $2.80.It will be paid on Mar. 24.  Full Article

AstraZeneca PLC reaffirms FY 2017 revenue guidance-Conference Call
Thursday, 6 Feb 2014 02:00am EST 

AstraZeneca PLC:Expects FY 2017 revenues will be broadly in line with FY 2013.FY 2017 revenues of $23.46 bln - Thomson Reuters I/B/E/S.  Full Article

Bristol-Myers Squibb Co completes previously announced sale of global diabetes business to AstraZeneca
Monday, 3 Feb 2014 02:00am EST 

Bristol-Myers Squibb Co:Says it has completed the previously announced sale of its global diabetes business to AstraZeneca.Receives from AstraZeneca a payment of about $2.7 bln in connection with the closing, and will receive by mid-February, a $0.6 bln payment from the recent U.S. approval of Farxiga (dapagliflozin).Says under terms of the agreement, Bristol-Myers Squibb will also receive from AstraZeneca potential regulatory and sales-based payments of up to $0.8 bln, and royalty payments based on net sales through 2025.Says AstraZeneca will make payments of up to $225 mln if and when certain assets are subsequently transferred.Says the transaction includes the rights to Bristol-Myers Squibb's global diabetes business that was part of its collaboration with AstraZeneca, the former Amylin manufacturing facility in West Chester, Ohio.Says also covers the future purchase by AstraZeneca of Bristol-Myers Squibb's Mount Vernon, Indiana, manufacturing facility, no earlier than 18 months following the closing date.Says the closing of the transaction as it relates to China remains subject to the satisfaction of certain conditions in the Sino-American Shanghai Squibb Pharmaceutical Company joint venture agreement between Bristol-Myers Squibb China and its joint venture partners.  Full Article

AstraZeneca PLC and Bristol-Myers Squibb XIGDUO receives approval in european union for type 2 diabetes
Wednesday, 22 Jan 2014 02:00am EST 

AstraZeneca PLC and Bristol-Myers Squibb:Says Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union (EU).Says Xigduo combines dapagliflozin (trade name Forxiga), a selective and reversible inhibitor of SGLT2 with metformin hydrochloride, two anti-hyperglycaemic products with complementary mechanisms of action to improve glycaemic control, in a twice daily tablet.Says this is the first regulatory approval for a fixed dose combination of an SGLT2 inhibitor and metformin.  Full Article

Photo

AstraZeneca taps Roche, Qiagen for new blood-based cancer drug tests

LONDON - AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.

Search Stocks